Chime Biologics and Mabgeek Achieve MG-K10 PPQ Milestone, Advancing Atopic Dermatitis and Asthma Therapies Antibody Drug MG-K10 Late-Stage Clinical Trials and Commercialization
Chime Biologics and Mabgeek Achieve MG-K10 PPQ Milestone, Advancing Atopic Dermatitis and Asthma Therapies Antibody Drug MG-K10 Late-Stage Clinical Trials and Commercialization -Process Performance Qualification (PPQ) validates robust manufacturing standards and is crucial for regulatory compliance -Marks a key step forward for the world’s first once-monthly IL-4Rα-targeting antibody therapeutic for Th2-driven diseases, with a strategic […]